What Is Poly-L-Lactic Acid (PLLA)?
Poly-L-lactic acid (PLLA) is a degradable synthetic polymer produced by fermentation and polymerization using natural plant sources such as corn and sugarcane. As early as the 1960s, it was widely used in medical applications including absorbable surgical sutures and orthopedic fixation screws, making it one of the most long-validated and data-rich biodegradable biomaterials in global medical use.
In aesthetic medicine, the core advantage of PLLA lies in its gradual regenerative mechanism. After administration, PLLA microspheres degrade slowly over approximately 18 to 24 months. The degradation products are metabolized through the lactic acid pathway and eventually eliminated from the body as carbon dioxide and water, without permanent residue. During this process, the microspheres gently and continuously stimulate dermal fibroblasts, inducing the orderly neogenesis of types I and III autologous collagen, ultimately improving skin elasticity and providing natural volume restoration.
Unlike hyaluronic acid, PLLA does not produce an immediate filling effect. Its clinical effects emerge gradually as collagen formation progresses, and the duration of results is typically longer and more natural.
Current Applications
2.1 Early Clinical Use: Starting from Specialized Indications
The aesthetic clinical use of PLLA dates back to around 2000. Its initial approved indication was the correction of HIV-related facial lipoatrophy. Extensive clinical data from this stage strongly validated the long-term safety of the material. Follow-up results exceeding 10 years demonstrated that, when performed appropriately, PLLA injection was associated with a lower incidence of late complications compared with traditional non-degradable filler materials.
As clinical experience accumulated, clinicians gradually expanded its application boundaries from the initial correction of atrophy to multiple scenarios in full facial rejuvenation.
2.2 Current Main Application Scenarios
Medical and Aesthetic Fields: Technologically Mature and Globally Established
In the aesthetic market, multiple PLLA-based injectable filler products have been approved globally, covering key anti-aging needs:
Facial volume reconstruction: For age-related mid-facial volume loss, temporal hollowing, and jawline laxity, deep-layer injection can provide osseous support and improve the collapsed appearance of the lower face.
Fine lines and skin texture improvement: For static periorbital rhytids, neck lines, and nasolabial folds, superficial injection stimulates collagen neogenesis and improves skin roughness and laxity at a deeper level.
Body area rejuvenation: Some products with broad approved indications may also be used for hand rejuvenation and subtle chest contouring as part of body volume restoration.
Combination therapy: An increasing number of treatment protocols combine PLLA with cross-linked hyaluronic acid, botulinum toxin, and CMC-based products. This approach integrates immediate shaping effects with long-term collagen regeneration, significantly improving patient satisfaction.
According to recent large-scale clinical studies, appropriately performed PLLA injection has demonstrated an overall patient satisfaction rate of over 90%, with sustained improvements in skin elasticity and hydration.
China’s Cosmetics Sector: New Raw Material Approval Opens New Industrial Chapter
For a long time, the application of PLLA in general cosmetics was limited by three technical bottlenecks: traditional processes could rarely control particle size below 100 μm, making it difficult to adapt to skincare formulations; the material itself is insoluble in water, creating major challenges for stable suspension and emulsification; and high-end imported PLLA microspheres could cost 200,000 to 300,000 RMB per kilogram, making widespread use in mass-market skincare impractical.
May 2026 marked a critical turning point for China’s PLLA industry. A domestically developed cosmetic raw material based on poly-L-lactic acid was officially filed and approved by the National Medical Products Administration (NMPA), filling a long-standing gap in domestic application of this category.
Today, the use of PLLA in China’s cosmetics sector is expanding rapidly:
As a gentle exfoliating ingredient, it can replace traditional plastic microbeads and irritating scrub particles, helping to protect sensitive skin barriers.
As a sensory modifier, it improves spreadability during application and creates a smooth, elegant skin feel.
As a film-forming ingredient, it supports long-lasting hydration and helps maintain skin oil–water balance.
Future applications may extend to cleansers, serums, creams, masks, color cosmetics, and even oral care products, opening new possibilities for daily anti-aging skincare.
Global Regulatory Landscape: Different Market Approaches
3.1 U.S. FDA Regulatory System
The United States is one of the earliest markets to establish formal regulatory oversight for PLLA injectable materials:
In 2004, the first PLLA injectable product was approved by the FDA, initially for the correction of HIV-related facial lipoatrophy.
Later, through the submission of additional clinical data, the indication was gradually expanded to include the improvement of facial wrinkles and volume restoration in general patients.
All PLLA injectable products are regulated as Class III medical devices, the highest risk category, requiring comprehensive long-term clinical safety data before and after market authorization.
3.2 EU EMA and Member State Regulation
In the European Union, PLLA regenerative materials are regulated under the CE certification framework:
All injectable PLLA products are classified as Class III medical devices. They must undergo rigorous assessment by a notified body and submit complete data on material characterization, toxicology, and clinical evaluation before receiving a CE certificate.
Several PLLA products are currently approved in different EU member states. Some products have indications covering both facial and selected body areas, reflecting a mature and well-established clinical compliance system.
3.3 China NMPA Regulatory Status
China maintains a strict and high-standard regulatory approach to PLLA injectable products:
All injectable PLLA fillers are managed as Class III medical devices, requiring complete domestic clinical trial data to verify long-term safety and efficacy.
In 2026, China’s regenerative materials market saw a concentrated wave of approvals. Four additional PLLA-based “collagen-stimulating filler” products received Class III medical device registration certificates during the year. Innovative products combining PLLA microspheres with cross-linked sodium hyaluronate have also emerged, aiming to combine the immediate shaping effect of hyaluronic acid with the long-term regenerative benefits of PLLA.
Supporting industry standards are also being improved. Domestic enterprises have led the formulation of relevant standards for medical-grade poly-L-lactic acid microspheres, establishing clear mandatory requirements for particle size distribution, degradation rate, biocompatibility, and other key indicators, thereby promoting standardized development across the industry.
In May 2026, domestically produced PLLA was officially approved as a new cosmetic raw material and is now subject to full life-cycle safety management in accordance with relevant regulations for new cosmetic ingredients.
Industry Trends
With the rapid development of the regenerative materials market, PLLA is evolving from a niche medical material to a widely accessible anti-aging ingredient. As domestic technological breakthroughs and regulatory refinement continue, this naturally derived biomaterial is expected to unlock value in an increasing number of application scenarios in the future.
References：
‑ Review on the Clinical Application of Injectable Poly‑L‑Lactic Acid (PubMed):00001. https://pubmed.ncbi.nlm.nih.gov/23379657/
‑ Research on Clinical Advances of Regenerative Materials, 2026 (Plast Reconstr Surg Glob Open): https://pmc.ncbi.nlm.nih.gov/articles/PMC12323926/
‑ Research on the Biomedical Applications of PLLA (Medicine (Baltimore)): https://pmc.ncbi.nlm.nih.gov/articles/PMC10939544/
‑ Industry Report on the Approval Status of Class‑III Medical Aesthetic Devices in China, 2026: https://www.c2cc.cn/news/20260722/125897.html
‑ Official FDA Approval Page for Poly‑L‑Lactic Acid Injectable Products:https://www.fda.gov/medical-devices/aesthetic-medicine-devices/poly-l-lactic-acid-sculptra
‑ EU CE‑Certified Injectable Medical Devices Regulatory Guidance:https://ec.europa.eu/growth/sectors/medical-devices/guidance_en